Piperazine derivatives with potent drug moiety as efficient acetylcholinesterase, butyrylcholinesterase, and glutathione S‐transferase inhibitors
Journal of Biochemical and Molecular Toxicology · 2023-02 · 37 (2)
DOI: 10.1002/jbt.23259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 23.11.2022. Verfasst von Mahmut Onur Karaytuğ und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Faculty of Medicine, Çukurova University, Adana, Turkey. Hauptthemen laut MEDLINE: Butyrylcholinesterase, Acetylcholinesterase. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Cholinesterases catalyze the breakdown of the neurotransmitter acetylcholine (ACh), a naturally occurring neurotransmitter, into choline and acetic acid, allowing the nervous system to function properly. In the human body, cholinesterases come in two types, including acetylcholinesterase (AChE; E.C.3.1.1.7) and butyrylcholinesterase (BChE; E.C.3.1.1.8). Both cholinergic enzyme inhibitors are essential in the biochemical processes of the human body, notably in the brain. On the other hand, GSTs are found all across nature and are the principal Phase II detoxifying enzymes in eukaryotes and prokaryotes. Specific isozymes are identified as therapeutic targets because they are overexpressed in various malignancies and may have a role in the genesis of other diseases such as neurological disorders, multiple sclerosis, asthma, and especially cancer cell. Piperazine chemicals have a role in many biological processes and have fascinating pharmacological properties. As a result, therapeutically effective piperazine research is becoming more prominent. Half maximal inhibition concentrations (IC 50 ) of piperazine derivatives were found in ranging of 4.59–6.48 µM for AChE, 4.85–8.35 µM for BChE, and 3.94‐8.66 µM for GST. Also, piperazine derivatives exhibited Ki values of 8.04 ± 5.73–61.94 ± 54.56, 0.24 ± 0.03–32.14 ± 16.20, and 7.73 ± 1.13–22.97 ± 9.10 µM toward AChE, BChE, and GST, respectively. Consequently, the inhibitory properties of the AChE/BChE and GST enzymes have been compared to Tacrine (for AChE and BChE) and Etacrynic acid (for GST).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Faculty of Medicine, Çukurova University, Adana, Turkey.
- Department of Chemistry, Faculty of Science, Atatürk University, Erzurum, Turkey.
- Department of Basic Sciences, Faculty of Dentistry, Iğdır University, Iğdır, Turkey.
- St. Elisabeth KrankenhausKlinik Fur Psychiatrie Und, Psychotherapie, Hattingen, Germany.
ORCID-Profile: Mahmut Onur Karaytuğ
Zitieren
APA
Karaytuğ, M. O., Balcı, N., Türkan, F., Gürbüz, M., Demirkol, M. E., Namlı, Z., Tamam, L., & Gülçin, İ. (2023). Piperazine derivatives with potent drug moiety as efficient acetylcholinesterase, butyrylcholinesterase, and glutathione S‐transferase inhibitors. Journal of Biochemical and Molecular Toxicology, 37(2). https://doi.org/10.1002/jbt.23259
Vancouver
Karaytuğ MO, Balcı N, Türkan F, Gürbüz M, Demirkol ME, Namlı Z, et al. Piperazine derivatives with potent drug moiety as efficient acetylcholinesterase, butyrylcholinesterase, and glutathione S‐transferase inhibitors. Journal of Biochemical and Molecular Toxicology. 2023;37(2). doi:10.1002/jbt.23259
BibTeX
@article{Karaytu2023,
author = {Karaytuğ, Mahmut Onur and Balcı, Neslihan and Türkan, Fikret and Gürbüz, Mahmut and Demirkol, Mehmet Emin and Namlı, Zeynep and Tamam, Lut and Gülçin, İlhami},
title = {Piperazine derivatives with potent drug moiety as efficient acetylcholinesterase, butyrylcholinesterase, and glutathione S‐transferase inhibitors},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2023},
volume = {37},
number = {2},
doi = {10.1002/jbt.23259}
}
EUVIMED